RALYL: A Potential Drug Target for Various Diseases (G138046)

Target Name: RALYL

NCBI ID: G138046

RALYL

RALYL: A Potential Drug Target for Various Diseases

RALYL (RALYL\\_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and muscle. It is a key regulator of the cell cycle, which means it helps keep cells dividing and growing in a controlled manner. RALYL is also involved in the development and maintenance of cancer, and has been identified as a potential drug target for various diseases.

The discovery and characterization of RALYL comes from a research group led by Dr. Xujiong Ye at the University of California, San Diego. Dr. Ye's team identified RALYL as a promising drug target after studying its functions in various cellular processes, including cell division, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels).

RALYL is a protein that is composed of 21 kDa monomers. It is expressed in various tissues of the human body, including the brain, heart, liver, and muscle. RALYL is a key regulator of the cell cycle, which means it helps keep cells dividing and growing in a controlled manner. It does this by playing a role in the replication of DNA in the cell, as well as the regulation of the cell cycle proteins that control the movement of chromosomes within the cell.

In addition to its role in the cell cycle, RALYL is also involved in the development and maintenance of cancer. Studies have shown that RALYL is highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. It is also associated with the development of resistance to chemotherapy in cancer cells.

RALYL has also been identified as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The potential drug targets for RALYL are based on its functions in cellular processes, including its role in the cell cycle, apoptosis, and angiogenesis.

In conclusion, RALYL is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and muscle. It is a key regulator of the cell cycle and is involved in the development and maintenance of cancer. RALYL has also been identified as a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the functions of RALYL and its potential as a drug target.

Protein Name: RALY RNA Binding Protein Like

The "RALYL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RALYL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets